Literature DB >> 17333129

Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application.

Jarogniew J Luszczki1.   

Abstract

The objective of this study was to characterize the anticonvulsant and acute adverse-effect potentials of topiramate (TPM) and gabapentin (GBP)-two second-generation antiepileptic drugs administered alone and in combination in the maximal electroshock (MES)-induced seizures and chimney test in mice. The anticonvulsant and acute adverse effects of the combination of TPM with GBP at the fixed ratio of 1:1 were determined using the type I isobolographic analysis for nonparallel dose-response relationship curves (DRRCs). To ascertain any pharmacokinetic contribution to the observed interaction between TPM and GBP, total brain concentrations of both drugs were determined. The isobolographic analysis of interaction for TPM and GBP, whose DRRCs were not parallel in both MES and chimney tests, was accompanied with a presentation of all required calculations allowing the determination of lower and upper lines of additivity. The isobolographic analysis revealed that TPM combined with GBP at the fixed-ratio combination of 1:1 interacted supraadditively (synergistically) in terms of suppression of MES-induced seizures, and simultaneously, the combination produced additive interaction with respect to motor coordination impairment (adverse effects) in the chimney test. The evaluation of pharmacokinetic characteristics of interaction for the combination of TPM with GBP revealed that neither TPM nor GBP affected their total brain concentrations in experimental animals, and thus, the observed interaction in the MES test was pharmacodynamic in nature. In conclusion, the combination of TPM with GBP, because of supraadditivity in the MES test and additivity in terms of motor coordination impairment in the chimney test as well as lack of pharmacokinetic interactions between drugs, fulfilled the criterion of a favorable combination, worthy of recommendation in further clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17333129     DOI: 10.1007/s00210-007-0144-z

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  31 in total

Review 1.  Antiepileptic drugs: safety in numbers?

Authors:  J P Leach
Journal:  Seizure       Date:  2000-04       Impact factor: 3.184

2.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

3.  Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin.

Authors:  N O Dalby; E B Nielsen
Journal:  Epilepsy Res       Date:  1997-07       Impact factor: 3.045

Review 4.  Interactions between drugs and occupied receptors.

Authors:  Ronald J Tallarida
Journal:  Pharmacol Ther       Date:  2006-09-07       Impact factor: 12.310

Review 5.  Use of animal models in developing guiding principles for polypharmacy in epilepsy.

Authors:  W Löscher; A Wauquier
Journal:  Epilepsy Res Suppl       Date:  1996

6.  Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model.

Authors:  Jarogniew J Luszczki; Neville Ratnaraj; Philip N Patsalos; Stanislaw J Czuczwar
Journal:  Epilepsia       Date:  2005-03       Impact factor: 5.864

7.  Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model.

Authors:  Jarogniew J Luszczki; Neville Ratnaraj; Philip N Patsalos; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-08       Impact factor: 3.000

8.  Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice.

Authors:  Jarogniew J Luszczki; Mariusz Swiader; Jolanta Parada-Turska; Stanisław J Czuczwar
Journal:  Neuropsychopharmacology       Date:  2003-10       Impact factor: 7.853

9.  Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis.

Authors:  Kinga K Borowicz; Mariusz Swiader; Jarogniew Luszczki; Stanislaw J Czuczwar
Journal:  Epilepsia       Date:  2002-09       Impact factor: 5.864

10.  Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

View more
  20 in total

1.  Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.

Authors:  Ewelina Gumbarewicz; Jarogniew J Luszczki; Anna Wawruszak; Magdalena Dmoszynska-Graniczka; Aneta J Grabarska; Agata M Jarząb; Krzysztof Polberg; Andrzej Stepulak
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.

Authors:  Anna Wawruszak; Estera Okon; Ilona Telejko; Arkadiusz Czerwonka; Jarogniew Luszczki
Journal:  Pharmacol Rep       Date:  2022-07-28       Impact factor: 3.919

3.  Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis.

Authors:  Anna Wawruszak; Jarogniew Luszczki; Estera Okon; Arkadiusz Czerwonka; Andrzej Stepulak
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

4.  Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.

Authors:  Paweł Marzęda; Paula Wróblewska-Łuczka; Małgorzata Drozd; Magdalena Florek-Łuszczki; Katarzyna Załuska-Ogryzek; Jarogniew J Łuszczki
Journal:  Int J Mol Sci       Date:  2022-06-17       Impact factor: 6.208

5.  Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves.

Authors:  Jarogniew J Luszczki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-20       Impact factor: 3.000

6.  Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.

Authors:  Jarogniew J Luszczki; Jim Z Wu; Grzegorz Raszewski; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-05       Impact factor: 3.000

7.  Differential molecular response of larynx cancer cell lines to combined VPA/CDDP treatment.

Authors:  Ewelina Gumbarewicz; Przemko Tylżanowski; Jarogniew Łuszczki; Joanna Kałafut; Arkadiusz Czerwonka; Justyna Szumiło; Anna Wawruszak; Krzysztof Kupisz; Krzysztof Polberg; Jolanta Smok-Kalwat; Andrzej Stepulak
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

8.  Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells.

Authors:  Aneta Grabarska; Jarogniew J Łuszczki; Ewa Nowosadzka; Ewelina Gumbarewicz; Witold Jeleniewicz; Magdalena Dmoszyńska-Graniczka; Krystyna Kowalczuk; Krzysztof Kupisz; Krzysztof Polberg; Andrzej Stepulak
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

Review 9.  Review about gabapentin misuse, interactions, contraindications and side effects.

Authors:  Gabriel C Quintero
Journal:  J Exp Pharmacol       Date:  2017-02-09

10.  Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.

Authors:  Anna Wawruszak; Jarogniew J Luszczki; Aneta Grabarska; Ewelina Gumbarewicz; Magdalena Dmoszynska-Graniczka; Krzysztof Polberg; Andrzej Stepulak
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.